Clinical trials
Cervical Cancer Recurrent clinical trials
Below are recruiting cervical cancer recurrent clinical trials, each written for real people, not researchers. We’re tracking 172 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04370496Recruiting
Testing minimally invasive endoscopic stapler surgery for early cervix cancer
This trial tests how safe a specific minimally invasive surgery tool (an endoscopic stapler) is for people with early-stage cervical cancer. If you qualify, you would get surgery to remove the cervix area using a minimally invasive approach and the study will track safety outcomes.
SeoulAges 20 years+ - NCT06155396RecruitingPhase 2
Targeted drug combo for advanced cervical cancer
This trial tests a combination of two drugs: an antibody-drug conjugate (RC48-ADC) that targets HER2 on cancer cells, plus an immunotherapy (Zimberelimab) that helps your immune system attack the cancer. It is for people with advanced cervical cancer whose prior platinum-based chemotherapy has stopped working.
Bengbu, AnhuiAges 18 years+ - NCT06420427Recruiting
Blood test to predict cervical cancer return after surgery
This trial uses a simple blood test to look for cancer DNA (ctDNA) and HPV DNA after cervical cancer surgery. The goal is to detect any return of the cancer early, so you and your doctor can act quickly.
Guangzhou, GuangdongAges 18 years+ - NCT07782164Recruiting
Irreversible electroporation for recurrent pelvic tumors
This study tests a new technique called irreversible electroporation (IRE) for treating pelvic tumors that have returned despite earlier treatment. IRE uses electrical pulses to destroy cancer cells without surgery, offering a potential option when other local treatments like surgery or radiation are not suitable.
Amsterdam, North HollandAges 18 years+ - NCT06140589Recruiting
Cadonilimab for advanced cervical cancer
This trial tests a new immunotherapy drug called cadonilimab for women with cervical cancer that has returned, spread, or is advanced. The goal is to see if it works well, how safe it is, and if it costs less than standard treatments.
Fuzhou, FujianAges 18–80 - NCT06416748Recruiting
Minimally invasive hysterectomy for low-risk cervical cancer
This study tests whether a less invasive type of hysterectomy (keyhole surgery) works well for women with very early-stage cervical cancer. It aims to find a safer, faster recovery option for low-risk tumors.
RomaAges 18 years+ - NCT07667192Recruiting
Re-treating gynecologic cancer with repeat radiation or ablation
This trial studies using additional radiation or tumor-destroying techniques for gynecologic cancer that has come back after previous radiation treatment. It helps doctors understand if this approach is safe and effective for women with recurrent disease.
Zamość, Lublin VoivodeshipAges 18 years+ - NCT07645625RecruitingPhase 4
Pembrolizumab outcomes study in cervical cancer
This study tracks how well pembrolizumab works in people with cervical cancer that has come back, spread, or not gone away. It includes two groups: one for those currently on or starting the drug, and one for those who stop early due to a good response or side effects.
AmsterdamAges 18 years+ - NCT06692166RecruitingPhase 3
New drug vs standard chemo for advanced cervical cancer
This trial tests a new drug called 9MW2821 against standard chemotherapy options for cervical cancer that has come back or spread. The goal is to see if the new drug works better than the usual treatments, and you must have already tried a platinum-based chemotherapy.
BeijingAges 18–75 - NCT07472153RecruitingPhase 2/Phase 3
Immunotherapy plus chemo for advanced cervical cancer
This trial tests adding immunotherapy drugs (PD-1 or PD-L1 inhibitors) to standard chemotherapy, with or without bevacizumab, for people with cervical cancer that has spread, persisted, or come back after treatment. The goal is to see which combination works better.
Minsk, LesnoyAges 18–75 - NCT06489795Recruiting
Laparoscopic surgery for early cervical cancer
This trial studies how well a less invasive laparoscopic surgery works for women with early-stage cervical cancer. If you have a small tumor and need a hysterectomy, this may be an option for you.
Ludwigsburg, Baden-WurttembergAges 18 years+ - NCT07439497RecruitingPhase 2
Shorter radiation with chemo for cervical cancer
This trial tests a shorter course of high-precision radiation therapy given at the same time as chemotherapy for cervical cancer that has not spread to distant organs. It aims to find if this approach is effective and safe for patients with locally advanced disease.
Seoul, Gangnam-guAges 20 years+ - NCT06123884RecruitingPhase 2/Phase 3
BAT1308 plus chemotherapy for PD-L1-positive cervical cancer
This clinical trial tests a new combination therapy (BAT1308 plus chemotherapy, with or without Avastin) for women with advanced cervical cancer that is PD-L1-positive and has not been previously treated with systemic therapy. The goal is to see if this combination can shrink tumors or slow disease progression.
Wuhan, HubeiAges 18–70 - NCT07418749RecruitingPhase 3
Testing a new drug for advanced cervical cancer after standard treatments
This trial is testing a new drug called SHR-A2102 against standard chemotherapy for people with advanced cervical cancer that has not responded to platinum-based chemotherapy and an immunotherapy (PD-1 or PD-L1 inhibitor). The goal is to see if the new drug works better and what side effects it may cause.
Guangzhou, GuangdongAges 18 years+ - NCT07424664RecruitingPhase 2
Combination targeted drug and immunotherapy for recurrent gynecologic cancers
This trial tests a combination of two new drugs—becotatug vedotin (targeted therapy) and zimberelimab (immunotherapy)—in people with recurrent or metastatic cervical, vulvar, or vaginal cancer. The goal is to see if this combination works after standard treatments like platinum chemotherapy and immunotherapy have been tried.
Wuhan, HubeiAges 18–75 - NCT06670911RecruitingPhase 2
Lower dose pembrolizumab with chemo for advanced cervical cancer
This trial tests a lower dose of pembrolizumab combined with standard chemotherapy as a first treatment for cervical cancer that has spread, come back, or cannot be removed by surgery. The goal is to see if this combination can help shrink tumors and slow the cancer's growth.
Rio de Janeiro, Rio de JaneiroAges 18 years+ - NCT07340489RecruitingPhase 2
Serplulimab for locally advanced cervical cancer
This trial tests a new immunotherapy drug, serplulimab, for people with locally advanced cervical cancer. The goal is to see if it can help shrink or control the cancer before standard treatments.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07256236RecruitingPhase 2
SKB264 plus QL1706 for advanced cervical cancer
This trial tests a combination of two drugs—SKB264 and QL1706—for women with cervical cancer that has come back or spread and is not curable with standard treatments. The goal is to see if this new combination can help shrink tumors or slow the disease.
Fuzhou, FujianAges 18 years+ - NCT07227077Recruiting
Physical activity study for older cancer survivors with chronic pain
This study uses a smartphone program to encourage physical activity in older adults who have survived cancer and have ongoing pain. It aims to learn how to best help you move more and feel better.
Milwaukee, WisconsinAges 65 years+ - NCT07196033Recruiting
Cervical cancer brachytherapy registry study
This study collects information from patients with cervical cancer who are receiving standard treatment with chemotherapy, radiation, and brachytherapy (a type of internal radiation). The goal is to learn more about how this treatment works in a real-world setting to improve care for future patients.
Mumbai, MaharashtraAges Any age - NCT06942416RecruitingPhase 2
Study of iparomlimab and tuvonralimab with chemoradiation for recurrent cervical cancer
This trial tests whether adding two immunotherapy drugs (iparomlimab and tuvonralimab) to standard chemoradiation can help people with cervical cancer that has returned or spread to a few new places. The goal is to see if this combination improves outcomes for those whose cancer is no longer responding to initial treatment.
Jinan, Shandong RecruitingAges 18–75 - NCT06459687RecruitingPhase 3
Socazolimab for first-line treatment of advanced cervical cancer
This phase 3 trial tests a new immunotherapy drug called socazolimab combined with chemotherapy as a first treatment for cervical cancer that has come back, spread, or cannot be removed with surgery or radiation. The goal is to see if it helps shrink tumors and improves survival.
Hefei, AnhuiAges 18–75 - NCT07092696RecruitingPhase 2
Immunotherapy and chemoradiation for cervical cancer
This study tests whether combining immunotherapy with chemotherapy, followed by radiation plus immunotherapy, can work better than standard treatment for cervical cancer. It aims to help patients whose cancer has not spread yet.
TianjinAges 18–75 - NCT07051486RecruitingPhase 2
SHR-A1811 for HER2-positive recurrent or metastatic cervical cancer
This trial tests a new drug, SHR-A1811, that targets a protein called HER2 found on some cervical cancer cells. It's for women whose cervical cancer has returned or spread and is not responding to other treatments.
Fuzhou, FujianAges 18–75
Hear when a new Cervical Cancer Recurrent trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for cervical cancer recurrent?
- Yes. Clin2 currently lists 172 recruiting cervical cancer recurrent studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a cervical cancer recurrent trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a cervical cancer recurrent trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.